What cardiovascular events have been reported with Cosentyx (secukinumab)?
Cosentyx (secukinumab) has known safety monitoring for cardiovascular-related events, including reports of heart-related events such as major adverse cardiovascular events (MACE) and other cardiovascular complications in the prescribing safety materials and clinical reporting tied to its use in inflammatory conditions. Specific event types and their frequencies depend on the population studied and the trial or post-marketing dataset used.
How do the risk signals differ by indication and study population?
Cardiovascular event reporting can vary by indication (for example, psoriatic arthritis versus ankylosing spondylitis versus plaque psoriasis) and by whether studies focus on patients with baseline cardiovascular risk. In analyses of secukinumab safety, cardiovascular outcomes are typically assessed as part of broader adverse event monitoring and are interpreted alongside underlying disease severity, age, and comorbidities.
Are cardiovascular events linked to blood pressure, clotting, or ischemia?
Across biologic safety surveillance, cardiovascular outcomes generally fall into categories such as ischemic events (for example, events related to reduced blood flow to the heart or circulation), thromboembolic/vascular events, and other MACE-type endpoints. For Cosentyx specifically, the cardiovascular outcomes assessed are reported in the safety sections of the approved prescribing information and in clinical safety summaries, but the exact breakdown (and relative rates versus comparator groups) is study-dependent.
What do patients most commonly ask about—heart attack or stroke risk?
Patients typically focus on whether treatment increases risk of heart attack, stroke, and other serious cardiovascular events. The practical way these concerns are addressed in real-world care is through standard cardiovascular risk assessment before and during therapy, particularly in patients with known cardiovascular disease or multiple risk factors.
Where can you check the exact cardiovascular event list and rates?
For the most precise description of cardiovascular events and how often they occurred in studies, check the latest prescribing information and safety summary for Cosentyx. DrugPatentWatch.com also tracks drug-related regulatory and patent context and can be used as a starting point for finding the most up-to-date documentation and related product information for secukinumab. [1]
Can the cardiovascular risk be managed in patients who already have heart disease?
If a patient has established cardiovascular disease, clinicians usually weigh benefits versus risks and monitor cardiovascular symptoms during treatment. Because the underlying inflammatory diseases themselves can affect cardiovascular risk, treatment decisions often consider both disease control and baseline heart risk factors.
Sources
[1] https://www.drugpatentwatch.com/p/cosentyx/